Andrew Larry Frelinger III on Activation of Platelets in Flow Cytometry
Andrew Larry Frelinger III, Director Emeritus, Center for Platelet Research Studies Corresponding Faculty, Dept. of Pediatrics at Harvard Medical School, shared on LinkedIn:
”I am very pleased to share this publication which came about through a great collaboration with the Steve Watson lab.
The paper explores activation of GPVI, CLEC-2 and PEAR1 using multivalent nanobodies.
Special thanks to Rachel Lamerton for spearheading the work, Elenya Martin for preparing the nanobodies, and Jax Perry for the performing and analyzing the spectral cytometry assays.
These fantastic tools may aid in the development of assays to assess platelet function disorders.
Enjoy!”
Read the full article in RPTH.
Article: A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1
Authors: Rachel E. Lamerton, Eleyna M. Martin, Jacqueline Perry, Adam F. Cunningham, Steve P. Watson, Andrew Larry Frelinger III
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke